Skip to main content

Belen Garcia Prats

My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences. Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR, holding more than one year experience working with oncologic mouse models in an ISO900 environment.

Institutions of which they are part

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Belen Garcia Prats

Belen Garcia Prats

Belen Garcia Prats

Institutions of which they are part

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences. Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR, holding more than one year experience working with oncologic mouse models in an ISO900 environment.

My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences and I obtained in 2020 a MSc in Molecular Biotechnology. Hence, I am passionate about biomedical research areas such as pharmacology and toxicology, cancer biology and molecular techniques.
My previous experience encompasses working in a clinical laboratory, being in charge of the realization of biochemical and immunological analysis on clinical simples. In addition, I was parto f a basic research group, where I worked with cell cultures for the study of type 2 diabetes mellitus pathogenesis.
Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR. I have obtained the laboratory animals handling accreditation, holding more than one year experience working with oncologic mouse models in an ISO900 environment.

Projects

SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH..

IP: -
Collaborators: Marc Miquel Moltó Abad, Olga Sánchez- Maroto Carrizo, Julia German Cortes, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats, Angels Alcina Mila, Maria Fidel Lledò, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro
Funding agency: EUROPEAN COMMISSION
Funding: 649580
Reference: SAFE-N-MEDTECHEC_H2020-NMBP2018
Duration: 01/04/2019 - 30/09/2023

Related news

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

Related professionals

Karla patricia Rojas Cuotto

Karla patricia Rojas Cuotto

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more
Alberto Arecchi

Alberto Arecchi

New Technologies and Craniofacial Microsurgery
Read more
Adriana Zucchiatti Llanos

Adriana Zucchiatti Llanos

Predoctoral researcher
Physiology and Pathophysiology of the Digestive Tract
Read more
Mª Jose Moreno Negreie

Mª Jose Moreno Negreie

Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.